KR20190043222A - Fermented puree vegetables composition for enhancing intestinal beneficial bacteria - Google Patents
Fermented puree vegetables composition for enhancing intestinal beneficial bacteria Download PDFInfo
- Publication number
- KR20190043222A KR20190043222A KR1020170135000A KR20170135000A KR20190043222A KR 20190043222 A KR20190043222 A KR 20190043222A KR 1020170135000 A KR1020170135000 A KR 1020170135000A KR 20170135000 A KR20170135000 A KR 20170135000A KR 20190043222 A KR20190043222 A KR 20190043222A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- composition
- bacteria
- puree
- intestinal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 241000894006 Bacteria Species 0.000 title claims abstract description 39
- 235000013311 vegetables Nutrition 0.000 title claims abstract description 29
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 25
- 230000000968 intestinal effect Effects 0.000 title abstract description 24
- 230000002708 enhancing effect Effects 0.000 title description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 9
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 6
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 3
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 3
- 244000186892 Aloe vera Species 0.000 claims abstract 2
- 210000000936 intestine Anatomy 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 235000021121 fermented vegetables Nutrition 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 15
- 244000005709 gut microbiome Species 0.000 abstract description 13
- 235000013325 dietary fiber Nutrition 0.000 abstract description 6
- 235000013376 functional food Nutrition 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000007413 intestinal health Effects 0.000 abstract description 3
- 235000013406 prebiotics Nutrition 0.000 abstract description 3
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract 3
- 241000219193 Brassicaceae Species 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 24
- 230000004151 fermentation Effects 0.000 description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- 240000007124 Brassica oleracea Species 0.000 description 6
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000009200 high fat diet Nutrition 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 5
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 241000605059 Bacteroidetes Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- -1 polyphenol compound Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A23Y2220/67—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 장내 유익균 증진 활성을 강화시키는 채소 발효 조성물에 관한 것으로, 좀 더 구체적으로, 본 발명은 장내 유익균 증진을 돕는 유효성분의 효율을 높일 수 있도록 퓨레 타입으로 제조된 채소 발효 조성물에 관한 것이다.The present invention relates to a fermented vegetable composition for enhancing intestinal benefit-bacterium-promoting activity. More specifically, the present invention relates to a fermented vegetable composition prepared in a puree form so as to enhance the efficiency of an effective ingredient for promoting beneficial bacteria in the intestines.
인간의 장내 생태계는 출생과 동시에 미생물이 서식하기 시작하여 유익균과 유해균이 균형을 유지하며 장내 미생물 균총을 형성하고 인간과 공생하며 상호작용을 통해 인간의 건강에 직·간접으로 영향을 미친다. 최근 미국 국립보건원(NIH)은 ‘인간 미생물 군집 프로젝트’를 통해 장내 미생물 균총과 질병과의 관계를 연구하여 미생물 균총의 불균형이 염증성 장질환 등의 발병에 중요한 원인을 제공함에 따라 장내 미생물 균총의 정상화의 중요성을 대두시켰다.The intestinal ecosystem of humans begins to live with microorganisms at the same time as birth, balances beneficial bacteria and harmful microorganisms, forms intestinal microflora, affects human health directly or indirectly through interaction with humans. Recently, the National Institutes of Health (NIH) has been studying the relationship between intestinal microflora and disease through the 'Human Microbial Community Project'. As the imbalance of microflora provides important causes for inflammatory bowel disease, .
2006년 과학저널 ‘네이처’에 발표된 비만과 장내 세균의 연관성 논문에 따르면 마른 사람과 비만인 사람 사이 장내 세균 분포가 다르며, 쥐를 이용한 실험을 통해 비만 쥐에서는 퍼미테쿠스(Firmicutes)에 속하는 세균이 박테로이데트(Bacteroidetes)에 속하는 세균보다 상대적으로 높은 구성비율을 보임을 확인하였다. 이후 장내 미생물과 인체에 대한 연구가 다양한 영역에서 진행되고 있으며, 장내 미생물총 개선을 통한 비만 억제 및 질환 치료 등을 위하여 장내 미생물 균총 개선제 개발이 필요하다.According to a 2006 article published in the journal Nature, Obesity and the relationship between intestinal bacteria According to the article, the distribution of intestinal bacteria is different between dry and obese people. Through the experiment using mice, the bacteria belonging to Firmicutes (Bacteroidetes) bacteria in a relatively high composition ratio. Since then, studies on intestinal microorganisms and the human body have been progressing in various fields, and development of intestinal microflora improving agents is required for the prevention of obesity and the treatment of diseases through total intestinal microorganism improvement.
한국 사람들은 그동안 십자화과 채소로 배추, 양배추 등을 먹어왔지만 이제는 케일, 브로콜리 등 서양 사람들이 즐겨먹는 십자화과 채소를 암예방을 위해 많이 섭취하는 추세에 있다. 또한 최근 건강에 대한 국민관심이 높아짐에 따라 매일 섭취하는 식품을 통하여 질병을 예방할 수 있는 기능성 식품 및 기능성 식품 소재 가공기술 연구가 활발히 진행되고 있는 추세이다.Koreans have been eating cabbage and cabbage as cruciferous vegetables, but now they are eating a lot of cruciferous vegetables such as kale and broccoli, which are enjoyed by Western people, to prevent cancer. In addition, as public interest in health has increased recently, studies on processing technology for functional foods and functional food materials that can prevent diseases through daily intake of foods have been actively conducted.
십자화과 채소를 유산균을 이용하여 발효할 경우 이차대사산물의 생성으로 인해 기존의 성분이 강화되거나 활성화 형태로 전환되어 그 효능이 배가되는 것을 확인할 수 있으며, 또한 발효가 끝난 채소를 착즙하고 일정량의 당을 첨가하여 상온에서 안정적인 형태로 보존할 수 있는 발효액 조성물에 대한 연구가 최근 활발하게 진행되고 있다. 하지만 발효가 끝난 채소를 착즙할 경우 유효성분의 용출 수준에 한계가 있고, 특히 채소 유래 불용성 식이섬유 부분이 버려지므로 배변 활동 혹은 장 건강을 위한 기능성 부위의 손실이라는 단점을 안고 있으므로, 장내 유익균 증진을 돕는 유효성분 및 식이섬유의 회수율을 높일 수 있는 퓨레 타입의 발효 조성물에 관한 연구는 미비한 실정에 있다. When the cruciferous vegetables are fermented with lactic acid bacteria, it is confirmed that the secondary metabolites are strengthened and the existing components are strengthened or converted to the activated form, and the effect is doubled. In addition, the fermented vegetables are juiced and a certain amount of sugar And a fermentation broth can be stored in a stable form at room temperature. However, when the fermented vegetables are squeezed out, there is a limit in the elution level of the active ingredient. In particular, since the insoluble dietary fiber portion derived from vegetables is discarded, it has disadvantages such as defecation activity or loss of functional site for intestinal health. There has been little research on a puree fermentation composition capable of increasing the recovering efficiency of active ingredients and dietary fiber.
이에, 본 발명자들은 안전하면서도 장내 유익균을 증진시키는 천연물 가공제품을 개발하고자 예의 연구 노력한 결과, 종래로부터 사용되어 안전성이 입증된 십자화과 채소류를 이용하여 퓨레 타입의 발효 조성물을 제조하여 상식할 경우, 착즙 형태의 발효 조성물보다 장내 유익균의 증진 활성에 탁월한 효과를 나타냄을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have intensively studied to develop a natural product processing product which is safe and beneficial to the intestinal beneficial bacteria. As a result, it has been found that when a fermented composition of a puree type is produced using conventionally used cruciferous vegetables, Of the present invention exhibits an excellent effect on the enhancing activity of the beneficial bacteria in the intestines than the fermented composition of the present invention.
상기한 목적을 달성하기 위하여, 본 발명은 십자화과 채소류를 락토바실러스 플란타룸 PMO 08(Lactobacillus plantarum PMO 08)로 발효하고 이를 퓨레 타입의 조성물로 제조하는 것을 특징으로 한다. 본 과제는 채소 발효 조성물을 퓨레 타입으로 제조하였을 때 착즙 형태의 발효 조성물보다 장내 유익균의 증진 효과가 더 우수하다는 사실을 밝힘으로써, 이상의 혼합물을 활용하여 장내 유익균 증진 활성을 강화시키는 식품 조성물을 제공하는 것이다.In order to accomplish the above object, the present invention is characterized in that cruciferous vegetables are fermented with Lactobacillus plantarum PMO 08 and prepared as a puree type composition. The present invention provides a food composition that enhances the beneficial effect of enteric bacteria in the intestines by enhancing intestinal beneficial bacteria in the intestinal tract by purifying the vegetable fermented composition by a puree method, will be.
본 발명은 십자화과 채소류 및 락토바실러스 플란타룸 PMO 08(Lactobacillus plantarum PMO 08)을 포함하여 장내 유익균 증진 활성을 강화시키는 기능성 채소 발효 식품 조성물을 제공한다. 본 발명의 채소 발효 조성물은 안전할 뿐만 아니라, 퓨레 타입으로 제조하여, 장내 유익균 증진을 돕는 유효성분 및 불용성 식이섬유의 회수율을 높일 수 있어, 장내 유익균 개선을 통한 비만 예방, 배변활동 및 장 건강 개선에 효과적일 것으로 예상한다.The present invention provides a fermented vegetable fermented food composition comprising a cruciferous vegetable and Lactobacillus plantarum PMO 08 to enhance the beneficial bacteria-promoting activity in the intestines. The vegetable fermented composition of the present invention can be safely used as well as being made into a puree type so as to increase the recovery rate of the active ingredient and the insoluble dietary fiber for promoting beneficial bacteria in the intestines and to prevent the obesity by improving the beneficial bacteria in the intestines, .
도 1은 고지방식이를 실험동물에 급여한 뒤 본 발명의 방법에 의해 제조된 퓨레 타입의 채소 발효 조성물 및 액상 타입 채소 발효 조성물을 각각 경구투여하고 분변을 이용한 장내 미생물 유전체 분석(Gut Microbiome Analysis)을 통해 장내 유익균 증진 활성을 비교한 그래프이다.
도 2는 도 1에서의 분석 방법을 통해 장내 유해균 억제 활성을 비교한 그래프이다.
도 3은 도 1에서의 분석 방법을 통해 장내 피르미쿠테스(Firmicutes)와 박테로이데테스(Bacteroidetes)의 변화 양상을 비교한 그래프이다.
도 4는 차세대 염기서열분석(NGS, next generation sequencing) 기법을 통해 장내 미생물 군집의 full scanning을 하여 본 발명의 방법에 의해 제조된 퓨레 타입의 채소 발효 조성물의 장내 미생물 균총 개선 효과를 측정한 그래프이다.FIG. 1 is a graph showing the results of Gut Microbiome Analysis of feces-type vegetable fermentation composition and liquid-type vegetable fermentation composition prepared by the method of the present invention, Of the present invention.
FIG. 2 is a graph comparing the inhibitory activity against enteric bacteria in the intestines through the analysis method of FIG.
FIG. 3 is a graph comparing changes in the intestinal Pirmicutes and Bacteroidetes through the analysis method in FIG. 1; FIG.
FIG. 4 is a graph showing the effect of improving the intestinal microflora of the fermented vegetable fermented composition prepared by the method of the present invention by full scanning of intestinal microbial communities through next generation sequencing (NGS) technique .
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
퓨레 타입의 채소 발효 조성물 제조Preparation of pure-fermented vegetable fermentation composition
본 발명의 장내 유익균 증진 활성을 강화시키는 퓨레 타입의 채소 발효 조성물을 제조하기 위하여 십자화과 채소류와 이소말토올리고당, 그리고 알로에베라쥬스를 혼합하여 파쇄한 후, 여기에 발효를 위한 유산균을 접종하고 발효 온도 30℃ 내지 35℃의 온도에서 발효시간 72 내지 120시간 동안 발효시켰다. 발효가 종료되면 마이크로밀을 이용하여 미분쇄하고 15 내지 20 mesh의 여과망에 여과하여 퓨레 타입의 혼합조성물을 제조하였다.In order to prepare the fermented vegetable fermented composition for enhancing intestinal beneficial microorganism enhancing activity of the present invention, cruciferous vegetables, isomaltooligosaccharide and aloe vera juice were mixed and pulverized, followed by inoculation with lactic acid bacteria for fermentation at a fermentation temperature of 30 RTI ID = 0.0 > 35 C < / RTI > for a fermentation time of 72 to 120 hours. After the fermentation was completed, the mixture was finely pulverized using a micromill and filtered through a filter net of 15 to 20 mesh to prepare a puree-type mixed composition.
상기 십자화과 채소류는 사용 목적 및 용도에 맞추어 종류를 다양하게 할 수 있으나, 바람직하게는 케일, 배추, 양배추, 무, 브로콜리, 유채, 겨자 등을 사용할 수 있다.The cruciferous vegetables may be variously selected according to the purpose and use of the cruciferous vegetables, but preferably kale, cabbage, cabbage, radish, broccoli, rape, mustard and the like can be used.
상기 이소말토올리고당은 발효를 촉진시키는 탄소원의 공급을 목적으로 사용되었으며, 포도당, 과당, 설탕, 프락토올리고당, 이소말토올리고당 등 사용자의 목적에 맞게 다양한 탄소원을 사용할 수 있으나, 바람직하게는 이소말토올리고당을 사용할 수 있으며, 더욱 바람직하게는 올리고당 함량이 무수물 기준 50% 이상인 이소말토올리고당을 20 내지 30 중량%로 투입하여 사용할 수 있다.The isomaltooligosaccharide has been used for the purpose of supplying a carbon source for promoting fermentation. Various carbon sources may be used for the purpose of the user such as glucose, fructose, sugar, fructooligosaccharide and isomaltooligosaccharide. Preferably, And more preferably 20 to 30% by weight of isomaltooligosaccharide having an oligosaccharide content of 50% or more based on anhydride may be used.
상기 유산균은 바람직하게는 락토바실러스 플란타룸(Lactobacillus plantarum) 균주라면 제한되지 않고 본 발명에 적용될 수 있지만, 더욱 바람직하게는 락토바실러스 플란타룸 PMO 08(Lactobacillus plantarum PMO 08)(KFCC-11028) 균주일 수 있다.The lactic acid bacterium preferably is not limited as long as it is a Lactobacillus plantarum strain and can be applied to the present invention. More preferably, the lactic acid bacterium is a strain of Lactobacillus plantarum PMO 08 (KFCC-11028) Lt; / RTI >
본 발명의 락토바실러스 플란타룸 PMO 08(Lactobacillus plantarum PMO 08)(KFCC-11028) 균주는, 대한민국 특허 제264361호 (2000. 5. 30)에 기재된 유산균으로, 담즙산을 탈포합하여 생체내에 혈중 콜레스테롤 저하효과를 나타내는 효과가 있으며, 위장에서의 생존율이 뛰어나고 장 부착능이 우수하다는 사실이 공지되어있다.The Lactobacillus plantarum PMO 08 (KFCC-11028) strain of the present invention is a lactic acid bacterium as described in Korean Patent No. 264361 (May 30, 2000), wherein bile acid is defatted in the blood to lower cholesterol It is known that there is an effect showing an effect, an excellent survival rate in the gastrointestinal tract, and an excellent ability to adhere a bowel.
본 발명의 일실시예에서는 1011/g인 유산균 원말을 0.01 중량%로 투입하였다.In one embodiment of the present invention, 0.01% by weight of a lactic acid bacterial strain of 10 11 / g was added.
발효 온도는 첨가되는 유산균이 생존가능한 온도이면 특별히 제한되지 아니하나, 바람직하게는 25℃ 내지 40℃일 수 있으며, 더욱 바람직하게는 30℃ 내지 35℃일 수 있다.The fermentation temperature is not particularly limited as long as it is a temperature at which the added lactic acid bacteria can survive, but it may preferably be 25 to 40 캜, and more preferably 30 to 35 캜.
발효 시간은 발효 기질 및 유산균의 종류에 따라 당업자가 적절히 선택할 수 있으며 이에 제한되지 않으나, 바람직하게 72 내지 120시간 동안 수행될 수 있다.The fermentation time may be suitably selected by those skilled in the art depending on the fermentation substrate and the kind of the lactic acid bacteria, but is not limited thereto, but preferably 72 to 120 hours.
상기 발효과정은, 발효 산물의 산도를 측정하여 이를 품질 지표로 삼아 일정 산도에 도달했을 때 종료할 수 있으며, 바람직하게 산도 0.8% 내지 1.5% 일 때 종료할 수 있고, 더욱 바람직하게는 산도 1.0% 내지 1.2%일 때 발효를 종료 시킬 수 있다.The fermentation process may be terminated when the acidity of the fermentation product is measured and used as a quality index to reach a certain acidity, preferably, when the acidity is in the range of 0.8% to 1.5%, more preferably 1.0% To 1.2%, the fermentation can be terminated.
상기 발효 종료 시에는 퓨레 타입의 조성물로 제조하기 위하여 내용물을 착즙하지 않고 미분쇄가 가능한 기기로 잘게 분쇄할 수 있으며, 바람직하게 마이크로밀을 이용하여 분쇄할 수 있다.At the end of the fermentation, the contents may be finely pulverized into a device capable of pulverizing the pulverized product without preparing juice, and may be pulverized using a micromill.
상기 여과 과정이 끝나면 유산균이 살아있는 상태로 두거나, 유산균을 멸균시킨 상태, 또는 55°Bx 이상이 되도록 기능성 당류를 첨가하여 상온에서 미생물의 증식이 억제된 형태로 장기간 보관할 수 있으나, 바람직하게 유산균을 멸균시킨 후 18℃ 이하로 냉동하여 보관할 수 있다.When the filtration process is completed, the lactic acid bacteria may be kept alive, the lactic acid bacteria may be sterilized, or the functional saccharide may be added to the solution at 55 ° Bx or more for a long period of time at a room temperature to inhibit the growth of microorganisms. Preferably, And then frozen at 18 ° C or lower.
본 발명의 퓨레 타입의 채소 발효조성물을 유효성분으로 포함하는 식품 조성물은 기능성 식품(functional food), 영양 보조제(nutritional supplement), 건강식품(health food) 및 식품 첨가제(food additives) 등의 모든 형태를 포함한다. 상기 유형의 식품 조성물은 당 업계에 공지된 통상적인 방법에 따라 다양한 형태로 제조할 수 있다.The food composition comprising the fermented vegetable fermented composition of the present invention as an active ingredient may be in any form such as a functional food, a nutritional supplement, a health food, and a food additive . Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.
퓨레 타입의 채소 발효 조성물의 장내 유익균 증진 활성 평가Assessment of enhancing activity of intestinal beneficial germ in the pure fermented vegetable composition
<실시예 1>에서의 방법으로 제조된 퓨레 타입의 채소 발효 조성물이, 발효 종료 후 착즙하여 액상 타입으로 제조한 발효 조성물과 비교하였을 때 장내 유익균 증진 활성이 강화된다는 사실을 검증하였다.It was verified that the fermented vegetable fermented composition prepared by the method in Example 1 was enhanced after juicing after fermentation to enhance the intestinal beneficidal activity as compared to the fermented composition prepared in liquid form.
우선 퓨레 타입의 채소 발효 조성물이 액상 타입의 채소 발효 조성물 보다 유효성분이 우수하다는 사실을 밝히기 위해 항산화활성을 측정하여 비교하였다.First, antioxidant activity was measured and compared in order to clarify that the puree fermented vegetable composition was more effective than the liquid fermented vegetable composition.
항산화능의 측정 방법은 구체적으로 다음과 같다.The method of measuring the antioxidant ability is as follows.
항산화 활성은 1,1-diphenyl-2-picryhydrazyl(DPPH)을 이용하여 시료의 자유라디칼 소거 활성을 측정하는 Blois의 방법(Blois MS 1958)을 일부 응용하여 측정하였다. 실험방법은 메탄올에 용해시킨 0.2mM DPPH 1mL에 상기 폴리페놀 화합물 측정 방법에서와 동일한 조건으로 추출한 각 시료를 에탄올에 녹인 시료 1mL을 첨가하여 실온에서 10분 동안 반응시킨 다음 ELISA reader(Bio-Rad, Hercules, model 680, CA, USA)를 사용하여 517nm에서 흡광도를 측정하였다. 대조군(control)은 시험용액을 첨가하지 않았고, 공시험(blank)은 DPPH를 첨가하지 않고 시료의 영향을 보정하였다. 자유 라디칼 소거 활성(EDA)은 다음 식으로 계산하였다.Antioxidant activity was measured by Blois' method (Blois MS 1958), which measures free radical scavenging activity of 1,1-diphenyl-2-picryhydrazyl (DPPH). For the experimental method, 1 mL of each sample extracted in ethanol was added to 1 mL of 0.2 mM DPPH dissolved in methanol under the same conditions as in the polyphenol compound determination method, and the mixture was reacted at room temperature for 10 minutes. Then, an ELISA reader (Bio-Rad, Hercules, model 680, CA, USA) was used to measure the absorbance at 517 nm. The control was not added with the test solution, and the blank was corrected for the influence of the sample without addition of DPPH. The free radical scavenging activity (EDA) was calculated by the following formula.
EDA(Electro Donating Ability, Inhibition %) = [1-{}]×100EDA (Electro Donating Ability%) = [1- { }] X 100
모든 항목의 시험은 3회 반복 측정하여 평균치로 나타내었다.The test of all items was repeated three times and expressed as an average value.
그 결과, [표 1]에서 보는 바와 같이 퓨레 타입으로 제조하였을 때, 액상 타입에 비해 항산화활성(EDA)이 약 22% 증가된 것을 확인하여 더 많은 항산화물질을 함유하고 있음을 확인할 수 있었다.As a result, as shown in [Table 1], it was confirmed that the antioxidative activity (EDA) was increased by about 22% as compared with the liquid type when prepared as pure type, and thus it was confirmed that it contained more antioxidant substances.
이어, 장내 유익균 증진 활성을 비교하기 위해 각 실험시료를 투여한 실험동물의 분변을 수집하여 장내 미생물 유전체 분석(Gut Microbiome Analysis)을 통해 유익균 증식 활성과 유해균 억제 활성에 대해 각각 평가하였다.In order to compare the promoting activities of intestinal beneficial germs, the feces of the experimental animals were collected and evaluated for the proliferative activity of the beneficial bacteria and the inhibitory activity of the fungicides by the intestinal microbiological analysis (Gut Microbiome Analysis).
이에 6주령 수컷 C57BL/6 mouse를 ㈜오리엔트바이오에서 구입하여 일정한 온도(23±1℃)와 습도(50±5%)하에서 흰쥐용 일반 고형사료(AIN-93G)로 1주간 적응시킨 후 총 8마리를 대상으로 실험에 사용하였다.A 6-week-old male C57BL / 6 mouse was purchased from Orient Bio Co., Ltd., and was adapted for 1 week with a general solid diet (AIN-93G) for a week under constant temperature (23 ± 1 ° C) and humidity (50 ± 5% Were used for the experiment.
먼저 적응기간이 끝난 후 정상(Normal) 상태에서의 분변을 각각 채취하였으며, 장내 미생물 균총 불균형을 유도하기 위하여 고지방식이(High-fat diet, 60%)를 2주간 급여한 후 분변을 채취하였다. 고지방식이로 장내 미생물 균총 불균형을 유도한 다음에는 각각 4마리씩 분리하여 고지방식이 급여와 함께 본 발명의 퓨레 타입의 채소 발효 조성물을 300 mg/kg b.w. 용량으로 1일 1회, 2주간 경구투여한 처리군과, 액상 타입의 채소 발효 조성물을 동일 용량 및 용법으로 2주간 경구투여한 처리군으로 나누어 각각의 분변을 채취하였다. 채취한 분변은 70℃ deep freezer에 보관하면서 실험에 사용하였다. 각각의 분변은 한국의과학연구원에서 분변 내 미생물 DNA 중합반응에 의한 장내세균 분석(Gut Microbiome Analysis)을 통해 유익균과 유해균의 변화 양상을 Real-time PCR로 측정하였으며, 각각의 실험은 5회 반복 측정하여 평균치로 나타내었다.At the end of the adaptation period, the feces were collected from the normal state. Feces were collected from the high-fat diet (60%) for 2 weeks to induce intestinal microflora imbalance. After induction of intestinal microflora imbalance by the high-fat diet method, each 4 animals were separated, and the fermented vegetable fermented composition of the present invention was fed at 300 mg / kg bw. And the liquid fermented vegetable composition was orally administered for 2 weeks in the same dose and the same manner, and each feces was collected. The collected feces were stored in a deep freezer at 70 ℃. Each fecal sample was analyzed by real-time PCR using the Gut Microbiome Analysis (Gut Microbiome Analysis) of the fecal bacterial DNA polymerization reaction in the fecal samples, and each experiment was repeated 5 times Respectively.
그 결과, [도 1]에서 보는 바와 같이 유익균의 종류인 비피도박테리움 속(Bifidobacterium spp.)과 락토바실러스 속(Lactobacillus spp.)의 변화 양상은 고지방식이 급여로 인해 감소되었다가 채소 발효 조성물 투여에 의해 다시 증가되는 결과를 보였으며, 이중 액상 타입 채소 발효 조성물 투여에 비해 본 발명의 퓨레 타입의 채소 발효 조성물을 투여하였을 때 유익균 증가폭이 더욱 큰 것을 확인할 수 있었다. 또한 [도 2]에서 보는 바와 같이 유해균의 종류인 클로스트리디움 속(Clostridium spp.)의 변화 양상에 있어서는 유익균의 결과와 반대로 고지방식이 급여에 의해 증가되었다가 채소 발효 조성물 투여에 의해 다시 감소되었으며, 이중 액상 타입 채소 발효 조성물 투여에 비해 본 발명의 퓨레 타입의 채소 발효 조성물을 투여하였을 때 유해균 감소폭이 더욱 큰 것을 확인할 수 있었다. As a result, as shown in FIG. 1, the change patterns of the Bifidobacterium spp. And Lactobacillus spp. Were decreased due to the high fat diet and the vegetable fermentation composition The results showed that the addition of the pure fermented vegetable fermented composition of the present invention to the liquid type vegetable fermented composition resulted in a larger increase in the beneficial bacteria. As shown in FIG. 2, the change of Clostridium spp., A kind of harmful bacteria, was increased by the addition of the high fat diet and decreased by the addition of the vegetable fermentation composition, , It was confirmed that the decrease in the number of harmful bacteria was greater when the fermented vegetable fermented composition of the present invention was administered, compared to the administration of the double-liquid type vegetable fermentation composition.
또한 문(Phylum) 단위인 피르미쿠테스(Firmicutes)와 박테로이데테스(Bacteroidetes)의 변화 양상을 측정하였는데, 인체 장내세균의 약 90%는 피르미쿠테스(후벽균)와 박테로이데테스(의간균)로 구성되어 있다. 비만, 고혈압, 대장질환자 등에게서 피르미쿠테스의 비율이 높고, 건강한 사람일수록 박테로이데테스의 비율이 높다. [도 3]에서 보는 바와 같이 고지방식이 급여로 인한 비만 유발시 피르미쿠테스의 비율이 상대적으로 증가하였으나, 채소 발효 조성물 투여시 피르미쿠테스가 감소하고 박테로이데테스의 비율이 다시 증가하는 결과를 보였으며, 이중 액상 타입 채소 발효 조성물에 비해 본 발명의 퓨레 타입의 채소 발효 조성물을 투여하였을 때 박테로이데테스의 증가폭이 더욱 큰 것을 확인할 수 있었다.In addition, we measured changes in the phylum units Firmicutes and Bacteroidetes. About 90% of the intestinal bacteria were found in the order of Pirimicutes (bacillus) and Bacteriodetes Bacillus). Obesity, hypertension, high cholinergic patients with a high proportion of pyromycetes, healthy people, the percentage of bacteriosis is high. As shown in FIG. 3, the proportion of pyromycetes was relatively increased when the high fat diet was induced by obesity, but when the vegetable fermentation composition was administered, the pyromycetes decreased and the ratio of bacteriodesis increased again , And it was confirmed that the increase of bacteriodetes was more remarkable when the fermented vegetable fermented composition of the present invention was administered than the liquid fermented vegetable fermented composition.
한편, 일차로 분석한 PCR 방식의 Gut microbiome analysis에 이어, 보다 발전된 기술 기반의 분석방법인 차세대 염기서열분석(NGS, next generation sequencing) 기법을 통해 Gut microbiome analysis full scanning을 진행하였는데, [도 4]에서 보는 바와 같이 정상군에 비해 고지방식이 급여시 장내 미생물의 다양성 측면에서 다소 비정상적인 diversity가 관찰되었으나, 본 발명의 퓨레 타입의 채소 발효 조성물 투여시 고지방식이를 통해 깨어진 미생물 군집 균형이 다시 상당한 수준으로 정상화되는 결과가 확인되었다.In addition, Gut microbiome analysis of the first PCR method followed by Gut microbiome analysis full scanning was performed through NGS (next generation sequencing), which is a more advanced technology-based analysis method (FIG. 4) As shown in FIG. 5, when the high-fat diet was more divergent in terms of the diversity of intestinal microbes than the normal group, when the fermented vegetable fermented composition of the present invention was administered, the microbial community balance, The results were normalized.
결국, 본 발명의 퓨레 타입의 채소 발효 조성물은, 발효 종료 후 착즙하여 액상 타입으로 제조된 채소 발효 조성물에 비해 장내 유익균 증진을 돕는 유효성분의 효율이 높고, 장내 유익균 증진을 돕는 프리바이오틱스(prebiotics)로서의 식이섬유 함량이 상대적으로 크게 높아 장내 유익균을 증가시키고 유해균을 억제하는 활성을 더욱 증진시킬 수 있음을 확인할 수 있었다.As a result, the pure fermented vegetable composition of the present invention is superior to the vegetable fermented composition prepared by liquid-phase fermentation after fermentation and has a high efficiency of an effective ingredient for promoting beneficial bacteria in the intestines and a prebiotics ), The content of dietary fiber was relatively high, and it was confirmed that the activity to inhibit harmful bacteria can be further enhanced by increasing the beneficial bacteria in the intestines.
따라서, 본 발명은 십자화과 채소류 및 락토바실러스 플란타룸 PMO 08(Lactobacillus plantarum PMO 08)을 이용하여 제조한 장내 유익균 증진 활성을 강화시키는 기능성 채소 발효 식품 조성물을 제공한다. 본 발명의 채소 발효 조성물은 착즙한 액상 타입이 아닌 전체식(whole food) 형태의 퓨레 타입으로 제조하여, 장내 유익균 증진을 돕는 유효성분의 효율이 높고, 특히 프리바이오틱스(prebiotics)로서의 식이섬유 함량이 상대적으로 크게 높아 장내 유익균을 증가시키고 유해균을 억제하는 활성을 더욱 강화시킬 수 있어 장내 미생물 균총 개선을 통한 비만 예방, 배변활동 및 장 건강 개선용 기능성 식품 제조에 효과적이어서 산업상 이용가능성이 높다.Accordingly, the present invention provides a functional vegetable fermented food composition which enhances intestinal beneficidal activity, which is produced by using cruciferous vegetables and Lactobacillus plantarum PMO 08 ( Lactobacillus plantarum PMO 08). The vegetable fermented composition of the present invention is prepared in a whole food type puree type rather than a juice liquid type so that the efficiency of an effective ingredient for promoting beneficial bacteria in the intestines is high and the content of dietary fiber as prebiotics Is relatively high, thereby increasing the beneficial bacteria in the intestines and further enhancing the activity of inhibiting the harmful bacteria. Thus, it is highly effective in the production of functional foods for the prevention of obesity, improvement of bowel activity and intestinal health by improving intestinal microbial flora.
Claims (2)
Lactobacillus plantarum PMO 08 was inoculated with the cruciferous vegetables, the isomaltooligosaccharides and aloe vera juice were mixed, and the mixture was inoculated and fermented at a temperature of 30 ° C to 35 ° C for 72 to 120 hours, Pulverized using a micromill and filtered through a filter net of 15 to 20 mesh to prepare a puree-type fermented composition, which enhances the promoting activity of enteric fruit bacteria in the intestines.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170135000A KR20190043222A (en) | 2017-10-18 | 2017-10-18 | Fermented puree vegetables composition for enhancing intestinal beneficial bacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170135000A KR20190043222A (en) | 2017-10-18 | 2017-10-18 | Fermented puree vegetables composition for enhancing intestinal beneficial bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190043222A true KR20190043222A (en) | 2019-04-26 |
Family
ID=66281184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170135000A KR20190043222A (en) | 2017-10-18 | 2017-10-18 | Fermented puree vegetables composition for enhancing intestinal beneficial bacteria |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190043222A (en) |
-
2017
- 2017-10-18 KR KR1020170135000A patent/KR20190043222A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2844266B1 (en) | Therapeutic use of chardonnay seed products | |
US20080102061A1 (en) | Use hydrolyzed medium containing microorganisms medicinally | |
JP2010285425A (en) | Agent for regulating composition ratio of intestinal bacterial flora | |
JP2010200611A (en) | Agent for preventing or ameliorating obesity | |
CN107530387B (en) | Oral composition containing Bifidobacterium and cruciferous vegetable | |
KR20200104126A (en) | Composition for improving, preventing or treating bone diseases comprising Lactobacillus sakei CVL-001 or culture medium thereof | |
Bertkova et al. | The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats | |
Li et al. | Apple polysaccharide could promote the growth of Bifidobacterium longum | |
KR20220059972A (en) | Lactobacillus fermented product containing vitamin K2, and composition for preventing or treating inflammation containing same | |
US12076356B2 (en) | Composition comprising Molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease | |
US11369647B2 (en) | Probiotics for inhibiting and preventing progression of renal diseases, and compositions for inhibiting and preventing progression of renal diseases comprising same | |
AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
KR101472190B1 (en) | Composition for preventing, treating or improving constipation comprising plant originated tyndalized lactic acid bacteria, Lactobacillus plantarum PMO08 dead cell as an active ingredient | |
JP2022522151A (en) | A composition for improving, preventing or treating a bone disease or a metabolic disease containing a novel Latilactobacillus casei CVL-001 strain or a culture medium thereof. | |
KR101809616B1 (en) | A probiotic strain from kefir with anti-obesity effect | |
JP2010254594A (en) | Agent for promoting proliferation of bacteroides in intestine | |
KR20190043222A (en) | Fermented puree vegetables composition for enhancing intestinal beneficial bacteria | |
Yang et al. | Effects of extracted oil of fermented Tartary buckwheat on lipid-lowering, inflammation modulation, and gut microbial regulation in mice | |
KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
KR101535077B1 (en) | The products containing probiotic Bifidobacterium lactis HY8101 having activity preventing from insulin resistance, which caused type 2 diabetes mellitus | |
KR102202092B1 (en) | Weissella koreensis nd824 strain having improved productivity of ornithine and composition comprisingng the same | |
CN112840017B (en) | Lactic acid bacteria, blood iron increasing agent and anemia improving agent | |
US20240252559A1 (en) | Composition for inhibition of differentiation of osteoclast precursor cells into osteoclasts, and composition for improving bone metabolism | |
KR102531783B1 (en) | Composition for Improving intestine function comprising 'Noeulchal'sorghum | |
RU2793287C2 (en) | Kimchi for the prevention or treatment of helicobacterpylori-related diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |